Clinical trial
Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease
NCT02264743 is registered in ClinicalTrials.gov with Royal Brompton & Harefield NHS Foundation Trust as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease
- Lead sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- November 30, 2013
- Completion date
- November 30, 2015
- Enrollment
- 60 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.